# GRADUATE CERTIFICATE IN PHARMACEUTICAL REGULATION

CENTRE of REGULATORY EXCELLENCE









#### **PROFESSOR JOHN LIM**

**Executive Director** Centre of Regulatory Excellence

**Senior Advisor** 

Ministry of Health Singapore

Chairman

Singapore Clinical Research Institute

essential to meeting this need as well as developing a talent pool of regulatory leaders.

We are pleased to offer the Graduate Certificate in Pharmaceutical Regulation - the first dedicated regulatory training that caters to your learning needs in Singapore, South-East Asia and Asia-Pacific – for regulatory professionals as well as healthcare professionals and researchers interested to know more about regulatory science. We welcome you to consider this opportunity to develop your knowledge and skills to advance your regulatory career and your effectiveness as a regulatory professional.

### **ASSOCIATE PROFESSOR SILKE VOGEL**

**Deputy Director** 

Centre of Regulatory Excellence

**Associate Dean** 

**Graduate Studies Duke-NUS Medical School**  Education is one of CoRE's key strategic thrusts as it works towards enhancing regional health systems in Asia-Pacific. Taking on the Duke-NUS learning philosophy, we recognise that an effective learning experience goes beyond increasing knowledge and understanding, but also develops advanced technical skills and soft skills such as critical thinking and problem-solving skills. These are important traits to be found in regulatory professionals, given the increasing complexity and emerging challenges in the regulatory landscape.

CoRE provides a neutral academic platform


for networking of health products regulatory

stakeholders in the Asia-Pacific, with a special

focus on South-East Asia, to promote capacity

development and innovation.

We encourage you to explore the opportunities offered by the Graduate Certificate Programme, including a rich and fulfilling learning experience that equips you with the necessary knowledge and skills for a rewarding career in pharmaceutical regulatory affairs.



In 2005, with firm support from the Singapore government, the National University of Singapore (NUS) and Duke University, two academic institutions with strong track records in research and education, committed to combine the unique medical education curriculum at Duke University School of Medicine with the academic rigour and rich resources offered by NUS, and to offer students an enriching and innovative educational experience.

Duke-NUS is located on the main campus of the largest healthcare group in the country, Singapore Health Services (SingHealth). This group collectively delivers multi-disciplinary care among 42 clinical specialties across a large network of hospitals, national specialty centres and polyclinics. Together, Duke-NUS and SingHealth constitute a leading, world class Academic Medical Centre embodying the goal of delivering the highest levels of patient care, education and research.

Guided by this theme, CoRE contributes to improving patient access to health products and also enhancing regional health systems and health security.

Launched in 2014 within Duke-NUS, CoRE promotes education, consultancy and a think tank approach.

CoRE's education activities serve as a key focus towards enhancing regulatory capabilities. Continuous, structured regulatory educational opportunities are necessary to enable stakeholders to keep pace with rapid advancements in technology, healthcare systems and the biomedical landscape. It is particularly important to address regulatory capacity needs to facilitate timely access to health products and to support the flourishing biomedical scene in Singapore and the Asia-Pacific.

CoRE aims to address these needs through the Graduate Certificate Programme in Pharmaceutical Regulation that is focused on the needs of the Asia-Pacific region. CoRE offers this programme within a neutral academic setting to facilitate learning, networking and collaboration, encouraging the growth of a community committed to regulatory excellence.

## STRATEGIC WAY TO DEVELOP YOUR CAREER

Through this Graduate Certificate Programme we aim to equip working professionals like yourself with updated scientific and regulatory knowledge and critical skills through application-based learning. The skillsets gained through this programme will help you assume diverse roles requiring regulatory science expertise within the public and private sectors.

An enhanced understanding of regulatory issues will better prepare you to facilitate innovation and pharmaceuticals development as well as provide a deeper appreciation of the basis of regulatory requirements, contributing to timely research and marketing authorisation decisions to support the healthcare systems.

## DEVELOPING ADEPT PROFESSIONALS




The programme is targeted at early and mid-career regulatory professionals from the public and private sectors who wish to enhance their regulatory competencies. It is also suitable for professionals from the healthcare sector, including biomedical researchers, product developers and policy makers who are interested in gaining insights on the impact and contributions of regulatory science to the wider healthcare environment.

## BROADEN YOUR WORLDVIEW

Guided by the Duke-NUS and CoRE education philosophy, the programme aims not only to impart knowledge and understanding, but also to facilitate significant networking amongst regulators, industry and other stakeholders. You will have the opportunity to meet international and regional experts with different backgrounds and these interactions will expand your worldview by providing global and regional insights and enhancing your understanding of different perspectives.

The curriculum will promote interdisciplinary inquiry and cover different skill sets and technical areas. Graduates will be more adept at effectively working and communicating within a team with an international outlook, given the diverse and international backgrounds of course participants.



Insights from
Asia-Pacific Leads

Cutting-Edge Topics

Valuable Networking
Opportunities

Robust Foundation

**Product Life Cycle**Approach

**Powered by** Global Thought Leaders

The Graduate Certificate curriculum is designed to expand your core skills and expose you to new competencies.



We are committed to providing a holistic learning experience through a robust curriculum which is structured to:



#### **IMPROVE**

...technical competencies and understanding of the guidelines that influence key regulatory processes



#### **FACILITATE**

...interaction and collaboration by providing opportunities for students to interact with regulatory stakeholders from different professional backgrounds and countries



#### NURTURE

...critical thinking skills of students to enable quality in regulatory decision-making across the product life cycle





## PROFESSOR SIR ALASDAIR BRECKENRIDGE

#### Chairman

Centre of Regulatory Excellence

#### **Former Chair**

UK Medicines & Healthcare products Regulatory Agency



A lifelong learning journey awaits you: a comprehensive regulatory curriculum to advance your competencies, flexibility to suit your learning needs, and opportunities to broaden your perspectives and expand your networks.



## PATH TO SUCCESS

As an advocate for continuous learning, we are excited to partner with you on your career development journey. To ensure that you are exposed to the full scope of knowledge, skills, and competencies for your career development, the course content is structured to broaden your perspectives and provide a holistic view of the regulatory ecosystem. It aims to deepen your understanding of the science underlying health product regulation and regulatory frameworks. It will also provide you with a practical and realistic view of what regulatory science involves through interactions with experts and practitioners from industry and national regulatory authorities.

Through the course modules, you will strengthen your foundations in regulatory science while understanding the basis for managing regulatory submissions and

processes, and making quality regulatory decisions. Review and discussion of cutting-edge scientific and regulatory topics will empower you to facilitate the development of regulatory strategy and policy, and strengthen your regulatory leadership capabilities.

To meet the objectives of the programme and achieve the learning outcomes, the Duke-NUS pedagogy framework has been incorporated. This pedagogy is an integration of lectures and Team-Based Learning, creating a novel approach that fosters the development of lifelong learners, problem solvers and critical thinkers. Emphasising the Duke-NUS Educational Philosophy, this framework promotes continuing education while offering the flexibility and accessibility required by working regulatory professionals.

## **STAY AHEAD**

The curriculum is tailored to be relevant, contemporary, and accessible through an emphasis on three themes that run across all the modules to:



#### ENHANCE

..proficiency in regulatory submissions nd reviews across product life cycle, and support good regulatory management and quality in decision-making.



#### SUPPORT

...innovation of product development and regulatory processes for timely access to new health products.



#### PROMOTE

...convergence, collaboration and partnership across stakeholders for an efficient and effective regulatory environment.

Building on these common themes, the programme will provide you with the relevant skillsets and mindset to deepen your understanding and lead you through the modules. With an emphasis on 'how to', you will leave with actionable plans on 'how to':


- Use knowledge of various regulatory systems and principles of product life cycle management to support quality decision-making in your organisation
- Leverage current regulatory platforms and resources to adopt and implement good regulatory practices
- Relate technical datasets to regulatory requirements and support good practices
- Advocate the role and contributions of regulatory professionals to the wider healthcare system

) )

### **CURRICULUM**

The programme structure below outlines the 4 subject areas you will focus on. To graduate, you will be required to complete a total of 4 modules out of the 8 modules offered, which can be completed within a year.

1 Fundamental • 1 Pre-Market Process • 1 Post-Market Activity • 1 Regulatory Trend



The flexible curriculum is designed to accommodate your busy work schedule, allowing you to plan your course of career development to meet your needs and interests. The programme is taught through a blended learning approach, engaging students like yourself,

through an online learning management system that delivers content, enables assessments, and allows for interaction. Each module will also feature a 5-day face-to-face workshop, specifically designed to accommodate the demanding work schedule of your full-time job.

## **ASSESSMENT MODE**

Activities during the course will be graded to fulfil academic requirements. Each course module will include formal and informal assessments guided by the Duke-NUS teaching pedagogy. You will be graded on individual and group tests as well as group presentations during class discussions.

#### andidature

The module credits which are valid for a period of five years, will provide the necessary flexibility for planning your schedule to complete this course, based on your work commitment.

#### **Continuation and Graduation Requirements**

If unable to complete or pass a module, you are allowed to re-take the module once. You may also choose to take a different module if applicable within the Graduate Certificate course.



## **COURSE DETAILS**



## **FUNDAMENTALS**

#### **FUNDAMENTALS OF PHARMACEUTICAL REGULATION**

GMS5011 • 4 MODULAR CREDITS

Regulation of pharmaceuticals is controlled by standards, guidelines and legal frameworks. The interactions among these and the stakeholders – industry, regulatory authorities, healthcare professionals and patients – are required for effective governance for safe, quality and efficacious medicines and timely access for patients.

This fundamental module provides the understanding of the contribution of the various stakeholders, functions and guidelines that shape the regulatory environment and impact the healthcare management scene. The concept of product life cycle will be also be explored among other contemporary regulatory approaches.

#### **Learning Outcomes:**

- Explain the basis of regulatory functions and the operational processes across the product life cycle for pharmaceutical products
- Describe the basic documentation required for regulatory submission and assessment, using the ICH Common Technical Dossier as a prototype
- Describe the interaction among the regulatory stakeholders and the implication on regulatory decision-making
- Describe the various platforms of regulatory interactions and the major contributions in shaping regulatory approaches and collaborations



## PRE-MARKET PROCESSES

(CHOOSE 1 OF THE 2 MODULES)

#### CHEMISTRY, MANUFACTURING AND CONTROLS

GMS5012 • 4 MODULAR CREDITS

Ensuring quality of healthcare products is one of the key pillars in regulatory responsibilities, for industry, manufacturers and regulators. The contribution of Chemistry, Manufacturing and Controls (CMC) to a successful control of quality in pharmaceutical products spans from product development and manufacture, process validation to post-market variation changes, as well as an optimal quality management system.

This module provides the foundation in understanding the regulatory science behind the development, manufacturing and control of pharmaceuticals, including the global guidances that shape the regulatory processes. Besides promoting good submissions and evaluation practices, the module aims to enhance regulatory convergence and cooperation on CMC regulation.

#### **Learning Outcomes:**

- Explain the domains and key requirements for CMC dossier information and assessment of pharmaceuticals
- Apply principles of ICH quality guidelines across various CMC datasets, including processes for life cycle management
- Identify the common areas of concerns in the CMC regulation, including issues of regulatory divergence and country specific requirements

#### **CLINICAL TRIAL DESIGN AND DATA ANALYSIS**

GMS5101 • 4 MODULAR CREDITS

The effective regulation of pharmaceuticals for safety and efficacy depends on the availability, understanding and appropriate implementation of relevant guidelines and the processes designed to ensure quality in decision-making. The requirements are frequently different from traditional clinical trials and specific to regulatory affairs.

This four-credit module provides the understanding for the unique requirements of clinical trials and clinical data meant to support regulatory evaluation and approvals.

#### **Learning Outcomes:**

- Describe the key requirements of clinical studies for regulatory approvals
- Explain the key requirements for the non-clinical and clinical dossier information and assessment of pharmaceuticals across the product life cycle
- Explain the basis of structured decision-making in benefitrisk assessment and communication



## **POST-MARKET PROCESSES**

(CHOOSE 1 OF THE 2 MODULES)

#### PHARMACOVIGILANCE AND RISK MANAGEMENT\*

#### GMS5111 • 4 MODULAR CREDITS

Pharmacovigilance is one of the key regulatory function that monitors the safe effective use of pharmaceuticals in the real-world healthcare setting. It has progressively included risk management planning, which encompasses appropriate drug use, signal detection and other risk minimisation activities, for better product life cycle management.

Within this module, the principles, frameworks and processes for pharmacovigilance will be introduced. Various platforms and partnerships among regulatory stakeholders for ensuring adequate and quality pharmacovigilance data will be also covered.

#### **Learning Outcomes:**

- Explain the guidelines and principles behind the regulatory frameworks and processes for pharmacovigilance and risk management plan
- Describe the ideal conditions, processes and systems to optimise data collection, collation and signal generation
- List the platforms and initiatives that is supporting pharmacovigilance and risk management, both regionally and globally
- Describe strategies for improving risk communication and stakeholder engagement

#### **POST-MARKET SURVEILLANCE AND ENFORCEMENT\***

#### GMS5113 • 4 MODULAR CREDITS

The assurance of safe and quality medicines in the market depends on a range of vital activities after the approval of a medicine by the authorities. This includes the continual monitoring offered by inspections and audits of facilities and testing of product quality. In this globalised environment, there is also an increasing need to leverage on networks to effectively detect lapses in product quality and services in a timely manner.

Key activities and roles essential for effective post-market control, will be introduced, including managing failures of conformance and compliance. Topics covered will include collaborations and networks for optimising post-market communications, and handling of substandard and falsified pharmaceuticals.

#### **Learning Outcomes:**

- Describe the regulatory activities required to ensure the safe, quality and efficacious use of medicines after entry into market
- Explain the contribution of post-market activities to product life cycle management
- List the platforms and initiatives that are supporting postmarket activities for timely regulatory interventions

#### \*Pending approval from NUS

## **REGULATORY TRENDS**

(CHOOSE 1 OF THE 2 MODULES)

#### **REGULATION OF CELL, TISSUE AND GENE THERAPIES**

#### GMS5103 • 4 MODULAR CREDITS

Advanced therapies, covering the scope of cellular, tissue and gene treatment modalities, is a rapidly advancing field that offers exciting new therapeutic possibilities and constantly challenges the regulatory environment to expedite access to these innovations.

Through this module, an understanding is gained on the various frameworks and practices regulating advanced therapies, including requirements for product evaluation and dossier submission for an effective product life cycle management. The module will interest students who are keen in global trending regulatory approaches and strengthening the skillsets to accommodate new innovation. There is also a focus on promoting convergence of regulatory approaches for advanced therapies.

#### **Learning Outcomes:**

- Describe the concepts of regulation of Advanced Therapies, covering cell, tissue and gene modalities for healthcare management
- Explain the differences among the various existing regulatory frameworks and regional requirements, as well as opportunities for convergence
- Explain the key requirements for the assessment of advanced therapies across the product life cycle

#### **BIOTHERAPEUTICS AND BIOSIMILARS**

#### GMS5104 • 4 MODULAR CREDITS

The advent of biotherapeutics and biosimilars highlighted the need for regulatory affairs to accommodate the rapidly evolving medical sciences, necessitating timely revisions in policies, processes and the technical knowledge in managing these new innovations and facilitating access to meet medical needs.

This four-credit module provides the background to the rise of these biologicals in healthcare, and the defining differences from traditional pharmaceuticals and generics. There is a focus on post-market activities which serve as the main guards for ensuring the safe use of these products.

#### **Learning Outcomes:**

- Describe the principles supporting the development and regulatory evaluation of biotherapeutics and biosimilars
- Evaluate and comment on the adequacy of data for the submission and assessment of biotherapeutics
- Identify the common areas of concerns in the regulation of biotherapeutics and biosimilars, in the context of pharmacovigilance and product life cycle management

#### **GENERIC MEDICINES**

#### GMS5105 • 4 MODULAR CREDITS

Generic medicines are becoming increasingly important as a means of providing access to affordable healthcare by helping to suppress rising healthcare costs.

This module aims to equip students with skills to assess the therapeutic equivalence of a generic medicinal product relative to a comparator, specifically with respect to bioavailability (BA) and bioequivalence (BE). Students will learn how to design and conduct appropriate bioavailability and bioequivalence studies in accordance with established international guidance documents, and to analyse the data from such studies.

#### **Learning Outcomes:**

- Explain the principles and regulatory requirements for a generic medicinal product and how they differ from those for an innovator product
- Define fundamental principles of pharmacokinetics, bioavailability, bioequivalence and biowaivers.
- Describe approaches and considerations when assessing bioequivalence for different dosage forms and special considerations





### **DR MARGARET HAMBURG**

**Special Advisor** *Centre of Regulatory Excellence* 

**Foreign Secretary**U.S. National Academy of Medicine


**Former Commissioner**U.S. Food and Drug Administration

66

To enable participants to make the greatest impact through their individual roles, CoRE's curriculum is enriched with invaluable guidance and real-world insights from global and regional thought leaders in regulatory affairs.

## READY TO LEAD FROM ASIA- PACIFIC

The certificate programme meets the need for a dedicated regulatory training programme in Asia-Pacific, as currently available training opportunities are mostly catered to learners in the U.S. and Europe. With a curriculum designed to meet specific regional needs, as well as being based in Singapore, students will be able to gain relevant knowledge to serve the needs of their respective countries while appreciating the increased accessibility to training opportunities and flexibility offered by the curriculum model. We envision new generations of skilled and confident professionals equipped to make science-based and quality regulatory decisions for a positive impact on healthcare.



## POWERED BY GLOBAL THOUGHT LEADERS

CoRE's academic setting, prominent reputation and strong international networks enable us to engage key opinion leaders as our external experts, faculty and speakers. They come from national regulatory authorities, noted companies, government agencies and industry associations.

These experts are recognised for their extensive real-world experience and contributions to regulatory and healthcare excellence. As a student, you will have the opportunity to engage with them in workshops, seminars, symposiums and conferences.



DR TATSUYA KONDO

Chief Executive
Pharmaceuticals and
Medical Devices Agency
Japan
Advisory Board, CoRE



DR PAUL HUCKLE
Chief Regulatory Officer
& Senior Vice President
GlaxoSmithKline
Advisory Board, CORE



DR JOSEPH SCHEEREN

Senior Vice President & Head

Global Regulatory Affairs

Bayer Healthcare

Advisory Board, CoRE



DR HANS-GEORG EICHLER
Senior Medical Officer
European Medicines Agency
Visiting Expert, CORE



18

DR MURRAY LUMPKIN

Deputy Director

Integrated Development Lead &
Global Regulatory Systems Initiatives
Bill & Melinda Gates Foundation

Visiting Expert, CoRE



A/PROF KRISANTHA WEERASURIYA

Consultant

Healthcare Systems with
Focus on Medicines

Visiting Expert, CORE



DR ANNE COOK
Biologicals Quality Assessor
Medicines & Healthcare
products Regulatory Agency
Visiting Expert, CORE



DR MOHEB NASR
Principal
Nasr Pharma Regulatory
Consulting
Visiting Expert, CoRE



A/PROF CHAN CHENG LENG
Group Director
Health Products Regulation Group
Health Sciences Authority
Adjunct Appointment, CORE



ADJUNCT A/PROF RAYMOND CHUA
Group Director
Health Regulation Group
Director (Covering)
Regulatory Compliance and
Enforcement Division
Ministry of Health
Singapore
Adjunct Appointment, CoRE



PRA LUCKY SLAMET
Former Head
National Agency of Food
and Drug Control
Indonesia
Visiting Expert, CORE



PROF GREGORY DANIEL

DEPUTY DIRECTOR

Duke-Margolis Center for

Health Policy

Visiting Expert, Core



DR WASSIM NASHABEH
Vice President & Global Head
Policy & International Operations
Pharma Technical Regulatory
Roche
Visiting Expert, CORE



Vice President
Science — Global Biologics
The United States Pharmacopeia
Visiting Expert, CoRE



DR.-ING STEPHAN ROENNINGER

Adjunct Assistant Professor
George Washington University

Director
Quality External Affairs, Amgen
Visiting Expert, CORE



MR WONG KUM CHEUN
Head Asia Pacific
Regulatory & Development Policy
Novartis Asia Pacific
Pharmaceuticals Pte Ltd
Visiting Expert, CoRE



DR SANNIE CHONG
Head

APAC Technical Regulatory Policy
APAC Policy at Genentech
a member of Roche

Visiting Expert, CORE



DR CYNTHIA SUNG
Adjunct Associate Professor
Health Services & Systems Research
Duke-NUS Medical School
Visiting Consultant
Health Sciences Authority
Founder and President
Rainbow Pharma Consulting

Adjunct Appointment, CoRE



DR KELLATHUR SRINIVASAN
Acting Director
Advanced Therapy Products Branch
Medicinal Products Pre-market
Cluster
Health Products Regulation Group
Health Sciences Authority
Adjunct Appointment, CoRE



A/PROF KENNETH HARTIGAN-GO
Associate Professor
Department of Strategic Management
Head
Stephen Zuellig School of
Development Management
Visiting Expert, CoRE



DR VALERIO REGGI
Consultant
Drug Regulatory Matters and
Pharmaceutical Policy
Visiting Expert, CoRE



#### **CONNECT WITH US**

**Duke-NUS Centre of Regulatory Excellence** 8 College Road Singapore 169857





+65 6601 5147



CoRE@duke-nus.edu.sg



CoREdukeNUS

